Wilms tumor 1 peptide–major histocompatibility complex (WT1-pMHC) (WT1-pMHC)

The Wilms tumor 1 (WT1) peptide–major histocompatibility complex (pMHC) is a specialized molecular target for cancer immunotherapy, representing an intracellular protein fragment displayed on the cell surface (Source: PubMed PMID: 24501219). WT1 is a zinc-finger transcription factor that is highly overexpressed in a wide range of hematological malignancies, such as acute myeloid leukemia, and various solid tumors, but has very restricted expression in healthy tissues (Source: UniProt P19544). Because WT1 is an intracellular protein, it cannot be targeted by traditional monoclonal antibodies; instead, it must be processed into peptides and presented by MHC class I molecules, typically HLA-A*02:01, to be recognized by the immune system (Source: PubMed PMID: 23486625). The recognition of this complex by T-cell receptors (TCRs) is the basis for several advanced therapeutic modalities, including TCR-engineered T cells (TCR-T) and TCR-mimetic antibodies. These therapies, such as the TCR-mimetic antibody ESK1 or the vaccine Galinpepimut-S, are designed to elicit or provide a direct cytotoxic response against cells presenting the WT1 peptide (Source: ClinicalTrials.gov). Clinical development of these agents focuses on patients who are HLA-matched and whose tumors demonstrate high WT1 expression, making these parameters essential biomarkers for patient selection. Safety considerations for targeting the WT1-pMHC complex include potential on-target off-tumor toxicity in tissues with low-level WT1 expression, such as the kidneys and hematopoietic stem cells. Overall, the WT1-pMHC complex serves as a high-value target for precision oncology, bridging the gap between intracellular oncogenic drivers and extracellular immune recognition.

Other names

WT1-HLA complexWT1 peptide-HLA-A*02:01Wilms tumor protein 1 peptide-MHCWT1-MHC class I complex

Recognition of the peptide-MHC complex by T-cell receptors or TCR-mimetic agents to trigger cytotoxic immune responses against tumor cells.